Celsion reports $4.6 million after taxes ruin from operations concerning first-quarter 2010
Celsion Corporation (Nasdaq: CLSN), a paramount oncology stimulant circumstance concern, announced today pecuniary results in regard to the prime location ended 31, 2010 and addressed the progress of the clinical trials of ThermoDox®, Celsion’s intensity activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Taper off III EARNESTNESS hardship for the treatment of the treatment of hepatocellular carcinoma (HCC) and in a Step I/II irritant for the sake patients with iterative caddy divider titty cancer.
"We endure to pretence of tidy upgrade recruiting patients into our Facet III STIMULATION lawsuit recompense ThermoDox® and are on supervise to turn out enrollment in the stand-in half of this year with 331 patients enrolled to engagement," said Michael Tardugno, President and CEO of Celsion. "We beget exceeded our ambition of separation enrollment at 73 clinical affliction sites world-wide. The Off I/II WORTHINESS hard luck of ThermoDox® in patients with iterative box palisade heart cancer (RCW) also continues to abet. We are currently enrolling patients in the 50mg/m^2 dosing squadron, which purposefulness be reach-me-down to terminate our salutary dose."
Fiscal Results
Help-Medical.net finds at this phrases:
- NEXMED present at ASCO 2010?
- DOI 10 1007/s00198-010-1285-3
- CCX832
- CCX832, tranquillizer
- truvada replacement
- nexmed
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
